Search Results - "Каннабиноидные рецепторы"

1

Academic Journal

ПАРАМЕТРЫ ПОХОДКИ КРЫС С ПЕРИФЕРИЧЕСКОЙ НЕЙРОПАТИЕЙ ПРИ ТРАНСПЛАНТАЦИИ МЕЗЕНХИМАЛЬНЫХ СТВОЛОВЫХ КЛЕТОК И ФАРМАКОЛОГИЧЕСКОЙ СТИМУЛЯЦИИ КАННАБИНОИДНЫХ РЕЦЕПТОРОВ II ТИПА

Source: Žurnal Grodnenskogo Gosudarstvennogo Medicinskogo Universiteta, Vol 21, Iss 4, Pp 388-392 (2023)

Subject Terms: мезенхимальные стволовые клетки, нейропатическая боль, седалищный нерв, каннабиноидные рецепторы, анализ походки, catwalk, Medicine

File Description: electronic resource

Relation: http://journal-grsmu.by/index.php/ojs/article/view/3073; https://doaj.org/toc/2221-8785; https://doaj.org/toc/2413-0109

Access URL: https://doaj.org/article/32a8ba388b984a9281c9d207787a55ed

View record in DOAJ Full Text Finder

2

Academic Journal

Pharmacological blockade of cannabinoid type II receptors and mesenchymal stem cell transplantation in a model of peripheral neuropathic pain ; Фармакологическая блокада каннабиноидных рецепторов II типа при трансплантации мезенхимальных стволовых клеток в модели периферической нейропатической боли

Authors: A.-M. V. Yerofeyeva, S. V. Pinchuk, S. N. Rjabceva, A. Yu. Molchanova, А.-М. В. Ерофеева, С. В. Пинчук, С. Н. Рябцева, А. Ю. Молчанова

Contributors: Исследование проведено на базе ГНУ «Институт физиологии НАН Беларуси» в рамках диссертационной работы за счёт средств республиканского бюджета.

Source: Acta Biomedica Scientifica; Том 8, № 6 (2023); 141-152 ; 2587-9596 ; 2541-9420

Subject Terms: фармакологическая блокада СВ2-рецепторов, neuropathic pain, sciatic nerve, cannabinoid receptors, pharmacological blockade of CB2 receptors, нейропатическая боль, седалищный нерв, каннабиноидные рецепторы

File Description: application/pdf

Relation: https://www.actabiomedica.ru/jour/article/view/4500/2688; Scholz J, Finnerup NB, Attal N, Aziz Q, Baron R, Bennett MI, et al. The IASP classification of chronic pain for ICD-11: Chronic neuropathic pain. Pain. 2019; 160(1): 53-59. doi:10.1097/j.pain.0000000000001365; Bouhassira D. Neuropathic pain: Definition, assessment and epidemiology. Rev Neurol (Paris). 2019; 175(1-2): 16-25. doi:10.1016/j.neurol.2018.09.016; Colloca L, Ludman T, Bouhassira D, Baron R, Dickenson AH, Yarnitsky D, et al. Neuropathic pain. Nat Rev Dis Primers. 2017; 3: 17002. doi:10.1038/nrdp.2017.2; Cavalli E, Mammana S, Nicoletti F, Bramanti P, Mazzon E. The neuropathic pain: An overview of the current treatment and future therapeutic approaches. Int J Immunopathol Pharmacol. 2019; 33: 2058738419838383. doi:10.1177/2058738419838383; Zhou Y, Yamamoto Y, Xiao Z, Ochiya T. The immunomodulatory functions of mesenchymal stromal/stem cells mediated via paracrine activity. J Clin Med. 2019; 8(7): 1025. doi:10.3390/jcm8071025; Ерофеева А.-М.В., Молчанова А.Ю. Влияние трансплантации аллогенных мезенхимальных стволовых клеток жировой ткани на ноцицептивные реакции и параметры походки крыс с экспериментальной периферической нейропатией. Весці Нацыянальнай акадэміі навук Беларусі. Серыя медыцынскіх навук. 2022; 19(4): 404-412. doi:10.29235/1814-6023-2022-19-4-404-412; Ерофеева А.-М.В. Влияние фармакологической блокады каннабиноидных рецепторов 1 типа на эффективность трансплантации мезенхимальных стволовых клеток при экспериментальной периферической нейропатии. Вестник ВГМУ. 2022; 21(6): 46-57. doi:10.22263/2312-4156.2022.6.47; Guo W, Chu YX, Imai S, Yang JL, Zou S, Mohammad Z, et al. Further observations on the behavioral and neural effects of bone marrow stromal cells in rodent pain models. Mol Pain. 2016; 12: 1744806916658043. doi:10.1177/1744806916658043; Guo W, Wang H, Zou S, Gu M, Watanabe M, Wei F, et al. Bone marrow stromal cells produce long-term pain relief in rat models of persistent pain. Stem Cells. 2011; 29(8): 1294-1303. doi:10.1002/stem.667; Siniscalco D, Giordano C, Galderisi U, Luongo L, de Novellis V, Rossi F, et al. Long-lasting effects of human mesenchymal stem cell systemic administration on pain-like behaviors, cellular, and biomolecular modifications in neuropathic mice. Front Integr Neurosci. 2011; 5: 79. doi:10.3389/fnint.2011.00079; Naruse K, Sato J, Funakubo M, Hata M, Nakamura N, Kobayashi Y, et al. Transplantation of bone marrow-derived mononuclear cells improves mechanical hyperalgesia, cold allodynia and nerve function in diabetic neuropathy. PLoS One. 2011; 6(11): e27458. doi:10.1371/journal.pone.0027458; Carey LM, Xu Z, Rajic G, Makriyannis A, Romero J, Hillard C, et al. Peripheral sensory neuron CB2 cannabinoid receptors are necessary for both CB2-mediated antinociceptive efficacy and sparing of morphine tolerance in a mouse model of antiretroviral toxic neuropathy. Pharmacol Res. 2023; 187: 106560. doi:10.1016/j.phrs.2022.106560; Rossi F, Bernardo ME, Bellini G, Luongo L, Conforti A, Manzo I, et al. The cannabinoid receptor type 2 as mediator of mesenchymal stromal cell immunosuppressive properties. PLoS One. 2013; 8(11): e80022. doi:10.1371/journal.pone.0080022; Roche R, Hoareau L, Bes-Houtmann S, Gonthier MP, Laborde C, Baron JF, et al. Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes. Histochem Cell Biol. 2006; 126(2): 177-187. doi:10.1007/s00418-005-0127-4; Xie J, Xiao D, Xu Y, Zhao J, Jiang L, Hu X, et al. Up-regulation of immunomodulatory effects of mouse bone-marrow derived mesenchymal stem cells by tetrahydrocannabinol pre-treatment involving cannabinoid receptor CB2. Oncotarget. 2016; 7(6): 6436-6447. doi:10.18632/oncotarget.7042; Ruhl T, Karthaus N, Kim BS, Beier JP. The endocannabinoid receptors CB1 and CB2 affect the regenerative potential of adipose tissue MSCs. Exp Cell Res. 2020; 389(1): 111881. doi:10.1016/j.yexcr.2020.111881; Василевич И.Б., Пинчук С.В., Лобанок Е.С., Волотовский И.Д. Морфофункциональное состояние мезенхимальных стволовых клеток жировой ткани крыс в условиях подавления окислительного стресса. Весцi Нацыянальнай акадэмii навук Беларусi. Серыя бiялагiчных навук. 2014; (2): 82-88.; Deuis JR, Dvorakova LS, Vetter I. Methods used to evaluate pain behaviors in rodents. Front Mol Neurosci. 2017; 10: 284. doi:10.3389/fnmol.2017.00284; Kappos EA, Sieber PK, Engels PE, Mariolo AV, D’Arpa S, Schaefer DJ, et al. Validity and reliability of the CatWalk system as a static and dynamic gait analysis tool for the assessment of functional nerve recovery in small animal models. Brain Behav. 2017; 7(7): e00723. doi:10.1002/brb3.723; Choi S, Choi HJ, Cheong Y, Lim YJ, Park HK. Internal-specific morphological analysis of sciatic nerve fibers in a radiofrequencyinduced animal neuropathic pain model. PLoS One. 2013; 8(9): e73913. doi:10.1371/journal.pone.0073913; Mert T, Kurt AH, Arslan M, Çelik A, Tugtag B, Akkurt A. Anti-inflammatory and anti-nociceptive actions of systemically or locally treated adipose-derived mesenchymal stem cells in experimental inflammatory model. Inflammation. 2015; 38(3): 1302-1310. doi:10.1007/s10753-014-0101-1; Ruhl T, Corsten C, Beier JP, Kim BS. The immunosuppressive effect of the endocannabinoid system on the inflammatory phenotypes of macrophages and mesenchymal stromal cells: a comparative study. Pharmacol Rep. 2021; 73(1): 143-153. doi:10.1007/s43440-020-00166-3; https://www.actabiomedica.ru/jour/article/view/4500

Availability: https://www.actabiomedica.ru/jour/article/view/4500
https://doi.org/10.29413/ABS.2023-8.6.13

View record from BASE

3

Academic Journal

SIGNIFICANCE OF OPIOID, CANNABINOID, BRADYKININ RECEPTORS AND КАТP-CHANNELS IN THE CARDIOPROTECTIVE EFFECT OF ADAPTATION TO COLD ; ЗНАЧЕНИЕ ОПИОИДНЫХ, КАННАБИНОИДНЫХ, БРАДИКИНИНОВЫХ РЕЦЕПТОРОВ И КАТФ-КАНАЛОВ В КАРДИОПРОТЕКТОРНОМ ЭФФЕКТЕ АДАПТАЦИИ К ХОЛОДУ

Authors: Nikita S. Voronkov, Leonid N. Maslov, Yuri V. Bushov, Никита Сергеевич Воронков, Леонид Николаевич Маслов, Юрий Валентинович Бушов

Contributors: Работа выполнена при поддержке РФФИ (грант № 20-315-90054). Эксперименты с налтрексоном проведены в рамках государственного задания 122020300042-4. В работе использовано оборудование Центра коллективного пользования «Медицинская геномика» Томского НИМЦ.

Source: Complex Issues of Cardiovascular Diseases; Том 12, № 3 (2023); 50-56 ; Комплексные проблемы сердечно-сосудистых заболеваний; Том 12, № 3 (2023); 50-56 ; 2587-9537 ; 2306-1278

Subject Terms: КАТФ-каналы, Ischemia/reperfusion, Cold adaptation, Opioid receptors, Cannabinoid receptors, Bradykinin receptors, КАТP-channels, Ишемия/реперфузия, Адаптация к холоду, Опиоидные рецепторы, Каннабиноидные рецепторы, Брадикининовые рецепторы

File Description: application/pdf

Relation: https://www.nii-kpssz.com/jour/article/view/1148/810; https://www.nii-kpssz.com/jour/article/downloadSuppFile/1148/1084; Oganov R.G. Maslennikova GYa. Noncommunicable diseases in Russia, the role of risk factors. In: Glazunov IS, Stachenko S, editors. Health promotion and prevention of noncommunicable disease in Russia and Canada. Experience and recommendations. Public Health Agency of Canada; 2006. p.3–18.; Ya'qoub L., Gad M., Saad A.M., Elgendy I.Y., Mahmoud A.N. National trends of utilization and readmission rates with intravascular ultrasound use for ST-elevation myocardial infarction. Catheter Cardiovasc Interv. 2021; 98(1): 1-9. doi:10.1002/ccd.29524.; Megaly M., Pershad A., Glogoza M., Elbadawi A., Omer M., Saad M., Mentias A., Elgendy I., Burke M.N., Capodanno D., Brilakis E.S. Use of intravascular imaging in patients with ST-segment elevation acute myocardial infarction. Cardiovasc Revasc Med. 2021; 30: 59-64. doi:10.1016/j.carrev.2020.09.032.; Sambola A., Elola F.J., Buera I., Fernandez C., Bernal J.L., Ariza A., Brindis R., Bueno H., Rodriguez-Padial L., Marin F., Barrabis J.A., Hsia R., Anguita M. Sex bias in admission to tertiary-care centres for acute myocardial infarction and cardiogenic shock. Eur J Clin Invest. 2021; 51(7): e13526. doi:10.1111/eci.13526.; Liakopoulos O.J., Schlachtenberger G., Wendt D., Choi Y.H., Slottosch I., Welp H., Schiller W., Martens S., Welz A., Neuhauser M., Jakob H., Wahlers T., Thielmann M. Early clinical outcomes of surgical myocardial revascularization for acute coronary syndromes complicated by cardiogenic shock: A Report From the North-Rhine-Westphalia Surgical Myocardial Infarction Registry. J Am Heart Assoc. 2019; 8(10): e012049. doi:10.1161/JAHA.119.012049.; Маслов Л.Н., Барбараш О.Л. Фармакологические подходы к ограничению размера инфаркта миокарда у пациентов с острым инфарктом миокарда. Экспериментальная и клиническая фармакология. 2018; 81(3): 75-82.; Цибульников С.Ю., Маслов Л.Н., Иванов В.В., Нарыжная Н.В., Цибульникова М.Р. Инфаркт-лимитирующий эффект адаптации к непрерывному холодовому воздействию. Рос физиол ж им И.М. Сеченова. 2016; 102(11): 1363-1368.; de Miranda D.C., de Oliveira Faria G., Hermidorff M.M., Dos Santos Silva F.C., de Assis L.V.M., Isoldi M.C. Pre- and post-conditioning of the heart: an overview of cardioprotective signaling pathways. Curr Vasc Pharmacol. 2021; 19(5): 499-524. doi:10.2174/1570161119666201120160619.; Maslov L.N., Naryzhnaia N.V., Tsibulnikov S.Y., Kolar F., Zhang Y., Wang H., Gusakova A.M., Lishmanov Y.B. Role of endogenous opioid peptides in the infarct size-limiting effect of adaptation to chronic continuous hypoxia. Life Sci. 2013; 93(9-11): 373-379. doi:10.1016/j.lfs.2013.07.018.; Maslov L.N., Khaliulin I., Oeltgen P.R., Naryzhnaya N.V., Pei J.M., Brown S.A., Lishmanov Y.B., Downey J.M. Prospects for creation of cardioprotective and antiarrhythmic drugs based on opioid receptor agonists. Med Res Rev. - 2016a; 36(5): 871-923. doi:10.1002/med.21395.; Maslov L.N., Khaliulin I., Zhang Y., Krylatov A.V., Naryzhnaya N.V, Mechoulam R., De Petrocellis L., Downey J.M. Prospects for creation of cardioprotective drugs based on cannabinoid receptor agonists. J Cardiovasc Pharmacol Ther. 2016; 21(3): 262-272. doi:10.1177/1074248415612593.; Atgie C., D'Allaire F., Bukowiecki L.J. Role of beta1- and beta3-adrenoceptors in the regulation of lipolysis and thermogenesis in rat brown adipocytes. Am J Physiol. 1997; 273(41): 1136-1142. doi:10.1152/ajpcell.1997.273.4.C1136.; Asimakis G.K., Inners-McBride K., Conti V.R., Yang C.J. Transient beta adrenergic stimulation can precondition the rat heart against postischaemic contractile dysfunction. Cardiovasc Res 1994; 28(11): 1726-1734. doi:10.1093/cvr/28.11.1726.; Cohen M.V., Downey J.M. Signalling pathways and mechanisms of protection in pre- and postconditioning: historical perspective and lessons for the future. Br J Pharmacol. 2015; 172(8): 1913-1932. doi:10.1111/bph.12903.; Heusch G. Molecular basis of cardioprotection: signal transduction in ischemic pre-, post-, and remote conditioning. Circ Res. 2015; 116(4): 674–699. doi:10.1161/CIRCRESAHA.116.305348.

Availability: https://www.nii-kpssz.com/jour/article/view/1148
https://doi.org/10.17802/2306-1278-2023-12-3-50-56

View record from BASE

4

Academic Journal

Synthetic cannabinoid: prevalence, mechanisms of addiction development, mental disorders associated with the use of synthetic cannabinoid

Authors: Andrey Viktorovich Antsyborov, Vladimir Valerievich Mrykhin

Source: Interactive science; № 4(14); 39-51
Интерактивная наука; № 4(14); 39-51

Subject Terms: каннабиноидные рецепторы, designer drugs, синтетические каннабиноиды, спайсы, synthetic cathinone, лабораторная диагностика, 01 natural sciences, 3. Good health, синтетические катиноны, mental addiction, spice, психозы, cannabinoid receptors, психическая зависимость, 0103 physical sciences, дизайнерские наркотики, psychosis, synthetic cannabinoids, laboratory diagnosis

File Description: text/html

Access URL: https://interactive-plus.ru/e-articles/351/Action351-117272.pdf
https://core.ac.uk/display/153649888
https://interactive-plus.ru/e-articles/351/Action351-117272.pdf
https://cyberleninka.ru/article/n/sinteticheskie-kannabinoidy-rasprostranyonnost-mehanizmy-formirovaniya-zavisimosti-psihicheskie-narusheniya-svyazannye-s
https://interactive-science.media/ru/article/117272/discussion_platform
https://cyberleninka.ru/article/n/sinteticheskie-kannabinoidy-rasprostranyonnost-mehanizmy-formirovaniya-zavisimosti-psihicheskie-narusheniya-svyazannye-s/pdf

View record at OpenAIRE

5

Academic Journal

Synthetic cannabinoids: new matrix addiction

Authors: Andrey Viktorovich Antsyborov, Vladimir Valerievich Mrykhin

Source: Interactive science; № 4(14); 25-38
Интерактивная наука; № 4(14); 25-38

Subject Terms: каннабиноидные рецепторы, designer drugs, классификация, review, лабораторная диагностика, обзор, synthetic cannabinoids withdrawal syndrome, spice, психозы, cannabinoid receptors, psychic dependence, психическая зависимость, psychosis, laboratory diagnosis, metabolites, 0505 law, 05 social sciences, синтетические каннабиноиды, спайсы, physical dependence, синдром отмены синтетических каннабиноидов, физическая зависимость, 3. Good health, classification, метаболиты, дизайнерские наркотики, 0509 other social sciences, synthetic cannabinoids

File Description: text/html

Access URL: https://interactive-plus.ru/e-articles/351/Action351-118680.pdf
https://interactive-plus.ru/e-articles/351/Action351-118680.pdf
https://interactive-science.media/ru/article/118680/discussion_platform
https://cyberleninka.ru/article/n/sinteticheskie-kannabinoidy-novaya-matritsa-addiktsii
https://cyberleninka.ru/article/n/sinteticheskie-kannabinoidy-novaya-matritsa-addiktsii/pdf

View record at OpenAIRE

6

Academic Journal

The use of cannabinoids in epilepsy as an example: medical, social, and legal aspects ; Применение каннабиноидов на примере эпилепсии: медицинские, социальные и юридические аспекты

Authors: R. G. Akzhigitov, K. I. Pochigayeva, F. K. Rider, A. M. Teplyshova, S. I. Dedayev, I. A. Shpak, E. V. Pashnin, A. B. Gekht, Р. Г. Акжигитов, К. И. Почигаева, Ф. К. Ридер, А. М. Теплышова, С. И. Дедаев, И. А. Шпак, Е. В. Пашнин, А. Б. Гехт

Source: Neurology, Neuropsychiatry, Psychosomatics; Vol 12, No 4 (2020); 125-130 ; Неврология, нейропсихиатрия, психосоматика; Vol 12, No 4 (2020); 125-130 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2020-4

Subject Terms: каннабиноидные рецепторы, cannabinoids, endogenous cannabinoid system, cannabinoid receptors, каннабиноиды, эндогенная каннабиноидная система

File Description: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/1422/1105; Russo EB. History of cannabis and its preparations in saga, science, and sobriquet. Chem Biodivers. 2007;4(8):1614-48. doi:10.1002/cbdv.200790144; Baron EP. Comprehensive review of medicinal marijuana, cannabinoids, and therapeutic implications in medicine and headache: what a long strange trip it's been…. Headache: J Head Face Pain. 2015;55(6):885-916. doi:10.1111/head.12570; Friedman D, Sirven JI. Historical perspective on the medical use of cannabis for epilepsy: Ancient times to the 1980s. Epilepsy Behav. 2017;70(Pt B):298-301. doi:10.1016/j.yebeh.2016.11.033; Touw M. The religious and medicinal uses of Cannabis in China, India and Tibet. J Psychoactive Drugs. 1981;13(1):23-34. doi:10.1080/02791072.1981.10471447; Lozano I. The Therapeutic use of Cannabis sativa (L.) in Arabic medicine. J Cannabis Ther. 2001;1(1):63-70. doi:10.1300/J175v01n01_05; Bonnie RJ, Whitebread CH. The Marijuana Conviction: A history of marijuana prohibition in the United States. Lindesmith Center; 1999.; Russo E. Cannabis for migraine treatment: the once and future prescription? An historical and scientific review. Pain. 1998;76(1-2):3-8. doi:10.1016/S0304-3959(98)00033-5; United Nations Office on Drugs and Crime. Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol. New York: United Nations; 2013. Available at: https://www.unodc.org/documents/commissions/CND/Int_Drug_Control_Conventions/Ebook/The_International_Drug_Control_Conventions_E.pdf; Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol. 2006;147 Suppl 1:S163-71. doi:10.1038/sj.bjp.0706406; Rosenberg EC, Tsien RW, Whalley BJ, Devinsky O. Cannabinoids and Epilepsy. Neurotherapeutics. 2015;12(4):747-68. doi:10.1007/s13311-015-0375-5; Adams R, Pease DC, Clark JH. Isolation of Cannabinol, Cannabidiol and Quebrachitol from Red Oil of Minnesota Wild Hemp. J Am Chem Soc. 1940;62(8):2194-6. doi:10.1021/ja01865a080; Mechoulam R, Shvo Y. Hashish I the structure of cannabidiol. Tetrahedron. 1963;19(12):2073-8. doi:10.1016/00404020(63)85022-X; Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc. 1964;86(8):1646-7. doi:10.1021/ja01062a046; Gaoni Y, Mechoulam R. The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashish. J Am Chem Soc. 1971;93(1):217-24. doi:10.1021/ja00730a036; Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids. II. Models for the prediction of time of marijuana exposure from plasma concentrations of Δ9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-Δ9-tetrahydrocannabinol (THCCOOH). J Analyt Toxicol. 1992;16(5):283-90. doi:10.1093/jat/16.5.283; Goodwin RS, Gustafson RA, Barnes A, et al. Delta(9)-tetrahydrocannabinol, 11hydroxy-delta(9)-tetrahydrocannabinol and 11nor-9-carboxy-delta(9)-tetrahydrocannabinol in human plasma after controlled oral administration of cannabinoids. Ther Drug Monit. 2006;28(4):545-51. doi:10.1097/00007691200608000-00010; Koppel BS, Brust JCM, Fife T, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82(17):1556-63. doi:10.1212/WNL.0000000000000363; Eisenberg E, Ogintz M, Almog S. The pharmacokinetics, efficacy, safety, and ease of use of a novel portable metered-dose cannabis inhaler in patients with chronic neuropathic pain: a phase 1a study. J Pain Palliative Care Pharmacother. 2014;28(3):216-25. doi:10.3109/15360288.2014.941130; Lu Y, Anderson HD. Cannabinoid signaling in health and disease. Can J Physiol Pharmacol. 2017;95(4):311-27. doi:10.1139/cjpp-20160346; Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365(6441):61-5. doi:10.1038/365061a0; Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors. Pharmacol Rev. 2002;54(2):161-202. doi:10.1124/pr.54.2.161; Quarta C, Bellocchio L, Mancini G, et al. CB1 signaling in forebrain and sympathetic neurons is a key determinant of endocannabinoid actions on energy balance. Cell Metabolism. 2010;11(4):273-85. doi:10.1016/j.cmet.2010.02.015; Marsicano G, Goodenough S, Monory K, et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science. 2003;302(5642):84-8. doi:10.1126/science.1088208; Wallace MJ, Blair RE, Falenski KW, et al. The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J Pharmacol Exp Ther. 2003;307(1):129-37. doi:10.1124/jpet.103.051920; Gebremedhin D, Lange AR, Campbell WB, et al. Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current. Am J Physiol. 1999;276(6):H2085-93. doi:10.1152/ajpheart.1999.276.6.H2085; Fimiani C, Mattocks D, Cavani F, et al. Morphine and anandamide stimulate intracellular calcium transients in human arterial endothelial cells: coupling to nitric oxide release. Cell Signal. 1999;11(3):189-93. doi:10.1016/S0898-6568(98)00060-6; Guo S, Liu Y, Ma R, et al. Neuroprotective effect of endogenous cannabinoids on ischemic brain injury induced by the excess microgliamediated inflammation. Am J Transl Res. 2016;8(6):2631-40.; Bravo-Ferrer I, Cuartero MI, Zarruk JG, et al. Cannabinoid type-2 receptor drives neurogenesis and improves functional outcome after stroke. Stroke. 2017;48(1):204-12. doi:10.1161/STROKEAHA.116.014793; Ford BM, Tai S, Fantegrossi WE, Prather PL. Synthetic Pot: Not Your Grandfather's Marijuana. Trends Pharmacol Sci. 2017;38(3):257-76. doi:10.1016/j.tips.2016.12.003; Chin JH, Vora N. The global burden of neurologic diseases. Neurology. 2014;83(4):349-51. doi:10.1212/WNL.0000000000000610; Hill AJ, Williams CM, Whalley BJ, Stephens GJ. Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacol Ther. 2012;133(1):79-97. doi:10.1016/j.pharmthera.2011.09.002; Jones NA, Hill AJ, Smith I, et al. Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J Pharmacol Exp Ther. 2010;332(2):569-77. doi:10.1124/jpet.109.159145; Hill TDM, Cascio M-G, Romano B, et al. Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism. Br J Pharmacol. 2013;170(3):679-92. doi:10.1111/bph.12321; Jones NA, Glyn SE, Akiyama S, et al. Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. Seizure. 2012;21(5):344-52. doi:10.1016/j.seizure.2012.03.001; Jones N, Hill A, Hill T, et al. Assessment of the anticonvulsant effects and tolerability profile of cannabidiol: GW Pharmaceuticals' Preclinical Program (P4.255). Neurology. 2015;84(14 Suppl):P4.255.; Dos Santos RG, Hallak JEC, Leite JP, et al. Phytocannabinoids and epilepsy. J Clin Pharm Ther. 2015;40(2):135-43. doi:10.1111/jcpt.12235; Shubina L, Aliev R, Kitchigina V. Endocannabinoid-dependent protection against kainic acid-induced long-term alteration of brain oscillations in guinea pigs. Brain Res. 2017;1661:1-14. doi:10.1016/j.brainres.2017.02.003; Reddy DS, Golub VM. The pharmacological basis of cannabis therapy for epilepsy. J Pharmacol Exp Ther. 2016;357(1):45-55. doi:10.1124/jpet.115.230151; Leo A, Russo E, Elia M. Cannabidiol and epilepsy: Rationale and therapeutic potential. Pharmacol Res. 2016;107:85-92. doi:10.1016/j.phrs.2016.03.005; Keeler MH, Reifler CB. Grand mal convulsions subsequent to marijuana use. Dis Nerv Syst. 1967;28(7, Pt. 1):474-5.; Consroe PF, Wood GC, Buchsbaum H. Anticonvulsant nature of marihuana smoking. JAMA. 1975;234(3):306-7. doi:10.1001/jama.1975.03260160054015; Feeney DM. The marijuana window: a theory of cannabis use. Behav Biol. 1976;18(4):455-71. doi:10.1016/S00916773(76)92488-3; Gordon E, Devinsky O. Alcohol and marijuana: effects on epilepsy and use by patients with epilepsy. Epilepsia. 2001;42(10):1266-72. doi:10.1046/j.1528-1157.2001.19301.x; Hamerle M, Ghaeni L, Kowski A, et al. Cannabis and other illicit drug use in epilepsy patients. Eur J Neurol. 2014;21(1):167-70. doi:10.1111/ene.12081; Gloss D, Vickrey B. Cannabinoids for epilepsy. Cochrane Database Syst Rev. 2012;(6):CD009270. doi:10.1002/14651858.CD009270.pub2; Cilio MR, Thiele EA, Devinsky O. The case for assessing cannabidiol in epilepsy. Epilepsia. 2014;55(6):787-90. doi:10.1111/epi.12635; Maa E, Figi P. The case for medical marijuana in epilepsy. Epilepsia. 2014;55(6):783-6. doi:10.1111/epi.12610; Saade D, Joshi C. Pure cannabidiol in the treatment of malignant migrating partial seizures in infancy: a case report. Pediatr Neurol. 2015;52(5):544-7. doi:10.1016/j.pediatrneurol.2015.02.008; Press CA, Knupp KG, Chapman KE. Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy. Epilepsy Behav. 2015;45:49-52. doi:10.1016/j.yebeh.2015.02.043; Porter BE, Jacobson C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav. 2013;29(3):574-7. doi:10.1016/j.yebeh.2013.08.037; Campbell CT, Phillips MS, Manasco K. Cannabinoids in pediatrics. J Pediatr Pharmacol Ther. 2017;22(3):176-85. doi:10.5863/1551-6776-22.3.176; Mathern GW, Beninsig L, Nehlig A. Fewer specialists support using medical marijuana and CBD in treating epilepsy patients compared with other medical professionals and patients: result of Epilepsia's survey. Epilepsia. 2015;56(1):1-6. doi:10.1111/epi.12843; Devinsky O, Cilio MR, Cross H, et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia. 2014;55(6):791-802. doi:10.1111/epi.12631; Devinsky O, Patel A, Cross J, et al. Effect of cannabidiol on drop seizures in the LennoxGastaut syndrome. N Engl J Med. 2018;378:1888-97. doi:10.1056/NEJMoa1714631; Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the dravet syndrome. N Engl J Med. 2017;376(21):2011-20. doi:10.1056/NEJMoa1611618; Devinsky O, Patel AD, Thiele EA, et al. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology. 2018;90(14):e1204-e1211. doi:10.1212/WNL.0000000000005254; Devinsky O, Nabbout R, Miller I, et al. Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial. Epilepsia. 2019;60(2):294-302. doi:10.1111/epi.14628; Szaflarski JP, Bebin EM, Comi AM, et al. Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results. Epilepsia. 2018;59(8):1540-8. doi:10.1111/epi.14477; Thiele E, Marsh E, MazurkiewiczBeldzinska M, et al. Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study. Epilepsia. 2019;60(3):419-28. doi:10.1111/epi.14670; Silvestro S, Mammana S, Cavalli E, et al. Use of cannabidiol in the treatment of epilepsy: efficacy and security in clinical trials. Molecules. 2019;24(8):1459. doi:10.3390/molecules24081459; Sekar K, Pack A. Epidiolex as adjunct therapy for treatment of refractory epilepsy: a comprehensive review with a focus on adverse effects. F1000Research. 2019;8(F1000 Faculty Rev):234. doi:10.12688/f1000research.16515.1; Ali S, Scheffer IE, Sadleir LG. Efficacy of cannabinoids in paediatric epilepsy. Dev Med Child Neurol. 2019;61(1):13-8. doi:10.1111/dmcn.14087; Friedman D, Devinsky O. Cannabinoids in the treatment of epilepsy. Longo DL, ed. N Engl J Med. 2015;373(11):1048-58. doi:10.1056/NEJMra1407304

Availability: https://nnp.ima-press.net/nnp/article/view/1422
https://doi.org/10.14412/2074-2711-2020-4-125-130

View record from BASE

7

Academic Journal